In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

European Journal of Heart Failure

Advancing knowledge in the field of heart failure management

 

The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management.

The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline.

Submit your paper

Fast Facts

  • Editor-in-chief: Michael Böhm (DE)
  • Current volume: 26 (year 2024)
  • Issues per subscription: 12
  • Impact Factor 2022:  18.2

Editor-in-chief History

Name Start Date End Date
Professor John Cleland 01/01/1999 31/12/2004
Professor Karl Swedberg 01/01/2005 31/12/2009
Professor Dirk J. Van Veldhuisen 01/01/2010 31/12/2014
Professor Marco Metra 01/01/2015 31/03/2024
Professor Michael Böhm 01/04/2024  
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blind peer review by experienced international experts.

Most recent articles from EJHF

15 May 2024
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
Author(s): Veraprapas Kittipibul, Robert J. Mentz, Robert M. Clare, Daniel M. Wojdyla, Kevin J. Anstrom, Eric L. Eisenstein, Andrew P. Ambrosy, Parag Goyal, Hal A. Skopicki, Fassil Ketema, Dong‐Yun Kim, Patrice Desvigne‐Nickens, Bertram Pitt, Eric J. Velazquez, Stephen J. Greene
14 May 2024
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial
Author(s): Muthiah Vaduganathan, Brian L. Claggett, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Akshay S. Desai, Pardeep S. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay‐Flurrie, John J.V. McMurray, Scott D. Solomon
15 May 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
Author(s): Mats Christian Højbjerg Lassen, John W. Ostrominski, Silvio E. Inzucchi, Brian L. Claggett, Ian Kulac, Pardeep Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Kieran F. Docherty, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
14 May 2024
Frailty according to the 2019 HFA‐ESC definition in patients at risk for advanced heart failure: Insights from the HELP‐HF registry
Author(s): Alessandro Villaschi, Mauro Chiarito, Matteo Pagnesi, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Ferdinando Loiacono, Antonio Maria Sammartino, Giada Colombo, Daniela Tomasoni, Riccardo Maria Inciardi, Marta Maccallini, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Cristiana Vitale, Giuseppe Massimo Claudio Rosano, Alberto Maria Cappelletti, Gianfranco Sinagra, Marco Metra, Daniela Pini